Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Not routinely available
SMC (SMC2143)
10/12/2018
Indication
As monotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a ≥50% TPS and progressing on or after platinum-containing chemotherapy.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Not routinely available as not recommended for use in NHSScotland
Formulation
25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion
Comments
None
Link to Advice
Advice Published
10/12/2018
SMC Submission Type
Non submission
SMC Status
Not recommended